Vaginal microbicides: Where are we and where are we going?

Journal of Infection and Chemotherapy

Volumn 14, Issue 5, 2008, Pages 337-341

  Moscicki, Anna Barbara ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; Immune markers; Vaginal microbicides

Indexed keywords

ACIDIFORM; BUFFERGEL DUET; C 31G; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE SULFATE; DAPIVIRINE; INVISIBLE CONDOM; LACTIN V; MICROBICIDE; MIV 150; MUCOCEPT; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PC 815; PRANEEM; PRO 2000; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAVVY; SURFACTANT; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

CLINICAL TRIAL; COLPOSCOPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NONHUMAN; PH MEASUREMENT; RELIABILITY; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX EPITHELIUM; VAGINA RING; VALIDATION PROCESS;

EID: 54349098502     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0630-3     Document Type: Review

References (12)

1. L. Van Damme G. Ramjee M. Alary B. Vuylsteke V. Chandeying H. Rees 2002 Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial Lancet 360 971 977
2. R.N. Fichorova L.D. Tucker D.J. Anderson 2001 The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission J Infect Dis 184 418 428
3. S.L. Hillier T. Moench R. Shattock R. Black P. Reichelderfer F. Veronese 2005 In vitro and in vivo: the story of nonoxynol 9 J Acquir Immune Defic Syndr 39 1 8
4. B.T. Galen A.P. Martin E. Hazrati A. Garin E. Guzman S.S. Wilson 2007 A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety J Infect Dis 195 1332 1339
5. J.H. van de Wijgert R.J. Shattock 2007 Vaginal microbicides: moving ahead after an unexpected setback AIDS 21 2369 2376
6. S.L. Lard-Whiteford D. Matecka J.J. O'Rear I.S. Yuen C. Litterst P. Reichelderfer 2004 Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update J Acquir Immune Defic Syndr 36 541 552
7. J.S. Smith N.J. Robinson 2002 Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review J Infect Dis 186 Suppl1 S3 S28
8. J.L. Schwartz C. Mauck J.J. Lai M.D. Creinin V. Brache S.A. Ballagh 2006 Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study Contraception 74 133 140
9. T.E. Taha D.R. Hoover G.A. Dallabetta N.I. Kumwenda L.A. Mtimavalye L.P. Yang 1998 Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV AIDS 12 1699 1706
10. H.L. Martin B.A. Richardson P.M. Nyange L. Lavreys S.L. Hillier B. Chohan 1999 Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition J Infect Dis 180 1863 1868
11. L. Myer L. Denny R. Telerant M. Souza T.C. Wright Jr L. Kuhn 2005 Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study J Infect Dis 192 1372 1380
12. L. Margolis R. Shattock 2006 Selective transmission of CCR 5-utilizing HIV-1: the "gatekeeper" problem resolved? Nat Rev Microbiol 4 312 317